Residency · Residency · Emergency Medicine
Post-Cardiac Arrest Care and Targeted Temperature Management
Pathophysiology of Post-Cardiac Arrest Syndrome
Four Components
Post-cardiac arrest syndrome is a distinct pathophysiologic entity with four interrelated components. Brain injury results from reperfusion injury, excitotoxicity, free radical damage, and cerebral edema — the brain suffers not only during the arrest itself but also when blood flow returns. Myocardial dysfunction, often called "stunned myocardium," manifests as transient global hypokinesis that peaks at 8 to 24 hours after ROSC but is usually reversible within 72 hours. The systemic ischemia-reperfusion response resembles a SIRS-like state with vasoplegia, coagulopathy, and adrenal suppression affecting every organ system. Finally, the persistent precipitating pathology — whatever caused the arrest in the first place, whether it was an acute coronary syndrome, pulmonary embolism, or toxin exposure — remains active and must be addressed.
Temporal Phases
Post-arrest care unfolds in distinct phases. The immediate phase (first 20 minutes) is marked by hemodynamic instability and ongoing risk of rearrest. The early phase (20 minutes to 6-12 hours) represents the window for targeted interventions like temperature management and coronary angiography. The intermediate phase (12-72 hours) is when organ injury evolves and neurologic assessment planning begins. The recovery phase (beyond 72 hours) is when neuroprognostication can finally begin with some reliability.
| Phase | Timeframe | Key Actions |
|---|---|---|
| Immediate | 0–20 min post-ROSC | Hemodynamic stabilization, 12-lead ECG, avoid rearrest |
| Early | 20 min–12 hours | TTM initiation, coronary angiography decision, ventilator targets |
| Intermediate | 12–72 hours | Continued TTM, seizure monitoring (cEEG), organ support |
| Recovery | > 72 hours | Neuroprognostication (multimodal assessment) |
Hemodynamic Optimization
Blood Pressure Targets
The target mean arterial pressure (MAP) is at least 65 to 80 mmHg, with some guidelines suggesting MAP above 80 mmHg to optimize cerebral perfusion. Any episode of systolic blood pressure below 90 mmHg is associated with worse outcomes, making hypotension avoidance a priority. Norepinephrine is the first-line vasopressor. When a cardiogenic component with low cardiac output is present, dobutamine or milrinone should be added.
Volume Assessment
Post-arrest patients are frequently both vasoplegic and volume-depleted. Point-of-care echocardiography is invaluable for assessing cardiac function and volume status at the bedside. Balanced crystalloids are preferred for volume resuscitation, and excessive normal saline should be avoided.
Early Coronary Angiography
For patients with ST-elevation on the post-ROSC ECG, immediate cardiac catheterization lab activation is a Class I recommendation. For patients without ST-elevation, the COACT trial (2019) demonstrated no benefit from immediate angiography compared to a delayed approach. Angiography should still be considered when suspicion for a coronary etiology is high even without STEMI, but its timing can be deferred, and it should never delay other critical interventions such as temperature management or CT imaging of the head.
Targeted Temperature Management (TTM)
Historical Evolution
The evidence for temperature management after cardiac arrest has evolved substantially. The 2002 landmark trials (HACA and Bernard) established that therapeutic hypothermia at 32 to 34 degrees Celsius improved neurologic outcomes in VF arrest. The TTM trial in 2013 then showed no difference in mortality or neurologic outcome between 33 degrees and 36 degrees Celsius. Most recently, the TTM2 trial in 2021 compared hypothermia at 33 degrees to normothermia with early treatment of fever (target 37.8 degrees or below) and found no benefit from active cooling.
| Trial | Year | Comparison | Key Finding |
|---|---|---|---|
| HACA / Bernard | 2002 | 32–34°C vs. no cooling | Hypothermia improved neurologic outcomes in VF arrest |
| TTM | 2013 | 33°C vs. 36°C | No difference in mortality or neurologic outcome |
| TTM2 | 2021 | 33°C vs. normothermia (≤ 37.8°C) | No benefit from active cooling |
Current Practice
The current minimum standard is active fever prevention — maintaining a temperature of 37.5 degrees Celsius or below — for at least 72 hours after ROSC. Hyperthermia is independently associated with worse neurologic outcomes and must be strictly avoided. If an institution's protocol calls for active cooling, a target of 32 to 36 degrees Celsius for at least 24 hours is used, with rewarming at a controlled rate of 0.25 to 0.5 degrees per hour.
Cooling Methods
Surface cooling devices such as the Arctic Sun system and cooling blankets are widely available. Intravascular cooling catheters provide more precise temperature control. Cold IV saline boluses (30 mL/kg at 4 degrees Celsius) were once used in the prehospital setting, but this practice is no longer recommended based on the RINSE trial and PARAMEDIC2 substudy data. Simple ice packs, while accessible, are insufficient for sustained, precise cooling.
Complications of Cooling
Shivering is the most common complication and can be managed with buspirone, meperidine, magnesium, dexmedetomidine, or neuromuscular blockade. Bradycardia is expected but usually well tolerated. Electrolyte shifts are clinically important: hypokalemia develops during cooling as potassium shifts intracellularly, while hyperkalemia can occur during rewarming as potassium is released. Coagulopathy and an increased risk of infection from impaired immune function are additional concerns.
Ventilation and Oxygenation
Oxygen Targets
The FiO2 should be titrated to maintain an SpO2 of 94 to 98 percent. Hyperoxia (PaO2 above 300 mmHg) is associated with increased mortality due to oxidative stress. Immediately after ROSC, starting at 100 percent FiO2 is appropriate, but rapid weaning should follow as soon as reliable SpO2 monitoring is available.
Carbon Dioxide Targets
Normocapnia is the goal, with a target PaCO2 of 35 to 45 mmHg. Hypocapnia causes cerebral vasoconstriction and worsens brain injury, while hypercapnia causes cerebral vasodilation and may increase intracranial pressure. Continuous end-tidal CO2 monitoring should be used and correlated with arterial blood gas values.
Seizure Management
Post-Arrest Seizures
Seizures occur in 10 to 35 percent of comatose post-arrest patients and can be either clinical or subclinical (detectable only on EEG). Continuous EEG monitoring is recommended for all comatose survivors. Myoclonus, including Lance-Adams syndrome, is common after cardiac arrest and does not always indicate a poor prognosis — this is an important distinction that prevents premature withdrawal of care.
Treatment
Levetiracetam or valproate serves as the first-line anticonvulsant. Benzodiazepines are used for acute seizure cessation, and status epilepticus should be treated aggressively following standard protocols. Prophylactic anticonvulsants are not recommended.
Neuroprognostication
Timing
Prognostication should never occur before 72 hours after ROSC, or 72 hours after return to normothermia if TTM was used. Sedation and neuromuscular blockade confound the neurologic examination, and adequate time must be allowed for drug clearance before any conclusions are drawn.
Multimodal Assessment
No single test is sufficient to predict neurologic outcome, and a multimodal approach is mandatory. The clinical examination evaluates for bilateral absence of pupillary light reflexes at 72 hours or beyond, absent corneal reflexes, and motor responses of M1 (no response) or M2 (extensor posturing). EEG findings that suggest poor prognosis include burst suppression, unreactive background, and status epilepticus. Somatosensory evoked potentials (SSEPs) offer the most specific predictor: bilateral absence of the N20 cortical response is strongly associated with poor outcome. Neuroimaging may show diffuse cortical restricted diffusion on MRI (DWI) or loss of gray-white differentiation on CT. Biomarkers such as neuron-specific enolase (NSE) above 33 mcg/L at 48 to 72 hours are suggestive but not definitive, as values vary by assay and no single cutoff is absolute.
| Modality | Findings Suggesting Poor Prognosis | Timing |
|---|---|---|
| Clinical exam | Bilateral absent pupillary/corneal reflexes; motor M1–M2 | ≥ 72 hours post-ROSC |
| EEG | Burst suppression, unreactive background, status epilepticus | 24–72 hours |
| SSEP | Bilateral absent N20 cortical response | ≥ 24 hours |
| MRI (DWI) | Diffuse cortical restricted diffusion | 2–5 days |
| CT | Loss of gray-white differentiation | 24–48 hours |
| NSE biomarker | > 33 mcg/L (assay-dependent) | 48–72 hours |
Avoiding Self-Fulfilling Prophecy
Early withdrawal of life-sustaining treatment is the most common cause of death after cardiac arrest, and premature prognostication can lead to inappropriate withdrawal decisions. Multiple modalities must be used, no single test should drive the decision, and neurology consultation should be involved.
Glucose Management
Hypoglycemia (below 70 mg/dL) must be avoided, and glucose should be checked frequently during cooling. Marked hyperglycemia (above 180 mg/dL) should also be avoided. Moderate glucose control in the range of 140 to 180 mg/dL is reasonable. An insulin infusion may be needed, but clinicians should be aware that insulin sensitivity changes during rewarming, creating a risk of hypoglycemia.
<image>A timeline infographic illustrating the phases of post-cardiac arrest care. The horizontal axis represents time from ROSC, divided into four phases: immediate (0-20 min), early (20 min to 12 hours), intermediate (12-72 hours), and recovery (beyond 72 hours). Each phase is color-coded and lists the key interventions: hemodynamic optimization and 12-lead ECG in the immediate phase; TTM initiation, coronary angiography decision, and ventilator targets in the early phase; continued TTM, seizure monitoring with continuous EEG, and organ support in the intermediate phase; neuroprognostication beginning at 72 hours in the recovery phase.</image>
<image>A medical illustration showing the multimodal neuroprognostication approach after cardiac arrest. A central image of a brain is surrounded by five diagnostic modalities arranged in a circle: clinical examination (pupillary reflex testing depicted), EEG tracing showing burst suppression, SSEP waveform with absent N20, brain MRI showing diffuse restricted diffusion, and a blood tube labeled NSE. Arrows point from each modality to a central decision node labeled "Multimodal Assessment - No single test is sufficient." A clock showing 72 hours is prominently displayed to emphasize timing.</image>
<image>A comparison diagram of the TTM evolution. Three columns representing the three landmark eras: 2002 (HACA trial showing 32-34 degrees C benefit), 2013 (TTM trial showing 33 vs 36 degrees C equivalence), and 2021 (TTM2 trial showing hypothermia vs normothermia with fever prevention showing no difference). Each column includes the trial name, sample size, key finding, and a thermometer graphic showing the target temperature. An arrow at the bottom shows the paradigm shift from active cooling to strict fever prevention.</image>
Clinical Pearls
Hyperthermia is the enemy after cardiac arrest, and strict fever prevention at or below 37.5 degrees Celsius for at least 72 hours is the current minimum standard of care. The TTM2 trial has shifted practice away from routine active cooling to 33 degrees, though institutional protocols vary widely. Prognostic decisions should never be made before 72 hours post-normothermia, and they must always rely on multimodal assessment rather than any single test or finding. Post-arrest myocardial dysfunction is usually reversible by 72 hours, which means that early aggressive hemodynamic support is critical to bridge the patient through the recovery period. Both hyperoxia (PaO2 above 300 mmHg) and hyperventilation (PaCO2 below 35 mmHg) worsen neurologic outcomes and should be carefully avoided. STEMI on the post-ROSC ECG warrants immediate angiography, while non-STEMI patients can undergo delayed angiography based on the COACT trial findings. Continuous EEG monitoring is essential in comatose post-arrest patients to detect subclinical seizures that would otherwise go unrecognized. Potassium shifts during cooling and rewarming require frequent monitoring — hypokalemia during cooling and hyperkalemia during rewarming.
References
- Dankiewicz J, et al. TTM2 Trial: Hypothermia versus normothermia after out-of-hospital cardiac arrest. NEJM. 2021;384:2283-2294.
- Nielsen N, et al. TTM Trial: Targeted temperature management at 33 vs. 36 degrees C after cardiac arrest. NEJM. 2013;369:2197-2206.
- Lemkes JJ, et al. COACT Trial: Coronary angiography after cardiac arrest without ST-segment elevation. NEJM. 2019;380:1397-1407.
- Sandroni C, et al. ERC-ESICM Guidelines on Neuroprognostication. Intensive Care Med. 2022;48:261-283.
- Panchal AR, et al. 2020 AHA Guidelines: Post-cardiac arrest care. Circulation. 2020;142(suppl 2).
